Meeting
2012 ASCO Annual Meeting
Effect of short-duration chemoimmunotherapy plus radioimmunotherapy on response rates in relapsed follicular lymphoma: A U.K. NCRI Lymphoma Group Study, CR UK/07/038.
Authors
Timothy M Illidge
Manchester Cancer Research Centre, Manchester, United Kingdom
Timothy M Illidge , Andrew T. Bates , Andrew John Davies , Ruth Pettengell , Barry Andrews , Louise Dent , Grace Hampson , Maureen Zivanovic , Eve Gallop-Evans , John A. Radford , Peter W. M. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8056)
DOI
10.1200/jco.2012.30.15_suppl.8056
Abstract #
8056
Poster Bd #
33E
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).
First Author: Ruemu Ejedafeta Birhiray
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2018 ASCO Annual Meeting
90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.
First Author: Mariano Provencio-Pulla
Poster
2014 ASCO Annual Meeting
AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
First Author: John Leonard